The Coriell Institute for Medical Research will support one of the two new centers tasked with generating new reference sequences of the human genome.
read morePatients with acute myeloid leukemia (AML), a leukemia which arises from bone marrow tissue, often see remission following their initial treatment, but for patients whose cancer returns, there are few options. One such option is guadecitabine, a novel DNA hypomethylating drug which slows problematic changes to a person’s epigenetic profile, but the drug is ineffective in a select number of relapsed or refractory AML patients and there has not been a way to determine who stands to benefit and who does not.
read moreThe Coriell Institute for Medical Research is now participating in a prestigious SU2C Catalyst® grant from Stand Up To Cancer for the study of epigenetic therapy in treating urothelial cancer, a common form of cancer typically found in the bladder. Part of the project grant was moved to Coriell following its hiring of Jean-Pierre Issa, MD, as its new President and Chief Executive Officer.
read moreTwo new lines of induced pluripotent stem cells are now available to researchers through the National Institute on Aging’s Aging Cell Repository, housed and distributed by the Coriell Institute for Medical Research. The addition of these two lines brings the total number of highly-characterized iPSC lines offered through this collection to five.
read moreThe Coriell Institute for Medical Research will attend this year’s American College of Medical Genetics and Genomics’ (ACMG) Annual Clinical Genetics Meeting. This year’s event is held in Seattle, Washington from April 2 until April 6.
read moreThe Coriell Institute for Medical Research received the inaugural Innovation Award from the Cooper’s Ferry Partnership at its annual meeting on Tuesday, March 5. This distinction recognizes Coriell’s role as a unique and critical resource to the global research community and its legacy of scientific foresight.
read moreThe Coriell Institute for Medical Research today announced it is expanding its leadership team by welcoming two skilled scientists to fill two new roles. Jaroslav Jelinek, M.D., Ph.D., will serve as the Institute’s new Chief Research Officer and Jozef Madzo, Ph.D., will join the Institute as its new Director of Bioinformatics. Both are scheduled to start on Feb. 28.
read moreJean-Pierre Issa, MD, a world-renowned expert in the epigenetics of cancer and director of Temple University’s Fels Institute for Cancer Research and Molecular Biology, will join the Coriell Institute for Medical Research as its new President and Chief Executive Officer, Coriell’s Board of Trustees Chairman Robert Kiep, III, announced today. His first day is scheduled for February 28, 2019.
read moreNew research from scientists at the Coriell Institute for Medical Research shows that some individuals whose bodies metabolize ibuprofen more slowly – causing the drug to be present at higher levels than intended – intuitively self-correct their dose without knowing their genetic makeup.
read moreThe Coriell Institute for Medical Research, Cooper University Health Care and Cooper Medical School of Rowan University (CMSRU) are launching the Camden Opioid Research Initiative (CORI), a first-of-its-kind undertaking to investigate the genetic and biological factors that contribute to the development of opioid use disorder (also referred to as opioid dependence or addiction). Opioid overdoses continue to climb in New Jersey and nationally and the opioid addiction epidemic is one of the most urgent public health concerns of our time. This year is the deadliest year of this epidemic in the Garden State.
read more